Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, preve...

Full description

Saved in:
Bibliographic Details
Published inEBioMedicine Vol. 79; p. 103993
Main Authors Dockrell, Hazel M., McShane, Helen
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.05.2022
Elsevier
Subjects
Advanced Basic Science
Internal Medicine
Personal View
SARS-CoV-2
Tuberculosis
Vaccines
SARS-CoV-2
Tuberculosis
Vaccines
Online AccessGet full text
ISSN2352-3964
2352-3964
DOI10.1016/j.ebiom.2022.103993

Cover

More Information
Summary:The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2022.103993